Prof Richard Grose
Professor of Cancer Cell Biology
Barts Cancer Institute
Faculty of Medicine and Dentistry, Queen Mary University of London
Faculty of Medicine and Dentistry, Queen Mary University of London
Research
Cellular crosstalk, 3D modelling, Breast Cancer, Pancreatic Cancer, Receptor tyrosine kinases, Fibroblast Growth Factors
Interests
We work with both cell line-based and primary cell-based 2D and 3D model systems, studying cellular crosstalk and tumour-stromal interactions in solid tumours - with a focus on breast and pancreatic cancer. We are particularly interested in interactions between luminal, myoepithelial and immune cells in the progression of Ductal Carcinoma in situ in the breast - including understanding how these cells interact with the surrounding stroma, with a particular focus on proteolytic activity. In pancreatic cancer, we are studying cancer-stellate cell interactions. We have expertise in studying a number of cell surface receptors and currently have projects involving FGFRs, EGFR, HER2, Cannabinoid receptors, Purinergic signalling and the Ephrin-Eph receptor axis.Publications of specific relevance to Predictive in vitro Models
2023
Rulten SL, Grose RP, Gatz SA, Jones JL and Cameron AJM (2023). The Future of Precision Oncology. MDPI International Journal of Molecular Sciences vol. 24, (16) Gibson SV, Madzharova E, Tan AC, Allen MD, Keller UAD, Jones JL, Carter EP and Grose RP (2023). ADAMTS3 restricts cancer invasion in models of early breast cancer progression through enhanced fibronectin degradation. Elsevier Matrix Biology vol. 121, 74-89. Clayton NS, Carter EP, Fearon AE, Heward JA, Fernández LR, Boughetane L, Wilkes EH, Cutillas PR and Grose RP (2023). HDAC Inhibition Restores Response to HER2-Targeted Therapy in Breast Cancer via PHLDA1 Induction. MDPI International Journal of Molecular Sciences vol. 24, (7) Bort ET, Joseph MD, Wang Q, Carter EP, Roth NJ, Gibson J, Samadi A, Kocher HM, Simoncelli S, McCormick PJ and Grose RP (2023). Purinergic GPCR-integrin interactions drive pancreatic cancer cell invasion. eLife eLife vol. 12, Gibson SV, Tomas Bort E, Rodríguez-Fernández L, Allen MD, Gomm JJ, Goulding I, auf dem Keller U, Agnoletto A, Brisken C, Peck B, Cameron AJ, Marshall JF, Jones JL, Carter EP and Grose RP (2023). TGFβ-mediated MMP13 secretion drives myoepithelial cell dependent breast cancer progression. Springer Nature npj Breast Cancer vol. 9, (1) Gibson SV, Roozitalab RM, Allen MD, Jones JL, Carter EP and Grose RP (2023). Everybody needs good neighbours: the progressive DCIS microenvironment. Elsevier Trends in Cancer vol. 9, (4) 326-338. Hayat A, Carter EP, King HW, Ors A, Doe A, Teijeiro SA, Charrot S, Godinho S, Cutillas P, Mohammed H, Grose RP and Ficz G (2023). Low HER2 enables dedifferentiation and transformation of normal breast epithelial cells via chromatin opening. The Company of Biologists Disease Models & Mechanisms vol. 16, (2) Azhar Z, Grose RP, Raza A and Raza Z (2023). In silico targeting of colony-stimulating factor-1 receptor: delineating immunotherapy in cancer. Open Exploration Publishing Exploration of Targeted Anti-tumor Therapy vol. 4, (4) 727-742. 2022
Coetzee AS, Carter EP, Rodríguez-Fernández L, Heward J, Wang Q, Karim SA, Boughetane L, Milton C, Uyulur F, Morton JP, Kocher HM and Grose RP (2022). Nuclear FGFR1 promotes pancreatic stellate cell-driven invasion through up-regulation of Neuregulin 1. Springer Nature Oncogene vol. 42, (7) 491-500. Yu Z, Zhang J, Zhang Q, Wei S, Shi R, Zhao R, An L, Grose R, Feng D and Wang H (2022). Single‐cell sequencing reveals the heterogeneity and intratumoral crosstalk in human endometrial cancer. Wiley Cell Proliferation vol. 55, (6) Zardab M, Stasinos K, Grose RP and Kocher HM (2022). The Obscure Potential of AHNAK2. MDPI Cancers vol. 14, (3) Mahmood HTNA, Tomas Bort E, Walker AJ, Grose RP and Chioni AM (2022). FGF signalling facilitates cervical cancer progression. Wiley The Federation of European Biochemical Societies (FEBS) Journal Murray ER, Menezes S, Henry JC, Williams JL, Alba-Castellón L, Baskaran P, Quétier I, Desai A, Marshall JJT, Rosewell I, Tatari M, Rajeeve V, Khan F, Wang J, Kotantaki P, Tyler EJ, Singh N, Reader CS, Carter EP, Hodivala-Dilke K, Grose RP, Kocher HM, Gavara N, Pearce O, Cutillas P, Marshall JF and Cameron AJM (2022). Disruption of pancreatic stellate cell myofibroblast phenotype promotes pancreatic tumor invasion. Elsevier Cell Reports vol. 38, (4) 2021
Chioni A-M and Grose RP (2021). Biological Significance and Targeting of the FGFR Axis in Cancer. MDPI Cancers vol. 13, (22) Joseph MD, Bort ET, Grose RP, McCormick PJ and Simoncelli S (2021). Quantitative Super-Resolution Imaging for the Analysis of GPCR Oligomerization. MDPI Biomolecules vol. 11, (10) Jomrich G, Kollmann D, Ramazanova D, Ristl R, Grose RP, Ilhan-Mutlu A, Preusser M, Fassnacht C, Tsai Y-C, Guenova E and Schoppmann SF (2021). Expression of programmed cell death protein 1 (PD-1) and programmed cell death 1 ligand (PD-L1) in adenocarcinomas of the gastroesophageal junction change significantly after neoadjuvant treatment. Elsevier European Journal of Surgical Oncology vol. 48, (2) 383-390. Carter EP, Roozitalab R, Gibson SV and Grose RP (2021). Tumour microenvironment 3D-modelling: simplicity to complexity and back again. Elsevier Trends in Cancer vol. 7, (11) 1033-1046. Jomrich G, Kollmann D, Wilfing L, Radosavljevic S, Ramazanova D, Ristl R, Grose RP, Ilhan-Mutlu A, Preusser M, Fassnacht C, Tsai Y-C, Guenova E and Schoppmann SF (2021). Programmed death ligand 2 expression plays a limited role in adenocarcinomas of the gastroesophageal junction after preoperative chemotherapy. Springer Nature European Surgery vol. 53, (6) 287-293. Carter EP, Coetzee AS, Tomas Bort E, Wang Q, Kocher HM and Grose RP (2021). Dissecting FGF Signalling to Target Cellular Crosstalk in Pancreatic Cancer. MDPI Cells vol. 10, (4) Adams SD, Csere J, D’angelo G, Carter EP, Romao M, Arnandis T, Dodel M, Kocher HM, Grose R, Raposo G, Mardakheh F and Godinho SA (2021). Centrosome amplification mediates small extracellular vesicle secretion via lysosome disruption. Elsevier Current Biology vol. 31, (7) 1403-1416.e7. Senga SS and Grose RP (2021). Hallmarks of cancer—the new testament. The Royal Society Open Biology vol. 11, (1) 2020
Wilcz‐Villega E, Carter E, Ironside A, Xu R, Mataloni I, Holdsworth J, Jones W, Moreno Béjar R, Uhlik L, Bentham RB, Godinho SA, Dalli J, Grose R, Szabadkai G, Jones L, Hodivala‐Dilke K and Bianchi K (2020). Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway. Springer Nature EMBO Molecular Medicine vol. 12, (2) 2018
Clayton NS and Grose RP (2018). Emerging Roles of Fibroblast Growth Factor 10 in Cancer. Front Genet vol. 9, 499-499. Fearon AE, Carter EP, Clayton NS, Wilkes EH, Baker A-M, Kapitonova E, Bakhouche BA, Tanner Y, Wang J, Gadaleta E, Chelala C, Moore KM, Marshall JF, Chupin J, Schmid P, Jones JL, Lockley M, Cutillas PR and Grose RP (2018). PHLDA1 Mediates Drug Resistance in Receptor Tyrosine Kinase-Driven Cancer. Elsevier Cell Reports vol. 22, (9) 2469-2481. 2017
Clayton NS, Wilson AS, Laurent EP, Grose RP and Carter EP (2017). Fibroblast growth factor-mediated crosstalk in cancer etiology and treatment. Dev Dyn vol. 246, (7) 493-501. Carter EP, Gopsill JA, Gomm JJ, Jones JL and Grose RP (2017). A 3D in vitro model of the human breast duct: a method to unravel myoepithelial-luminal interactions in the progression of breast cancer. Springer Nature Breast Cancer Research vol. 19, (1) 2016
Chioni A-M, Bajwa RT and Grose R (2016). 3D Organotypic Culture Model to Study Components of ERK Signaling. SpringerLink Methods Mol Biol vol. 1487, 255-267. GROSE RP, Dawkins JBN, Wang J, maniati , heward , koniali , kocher , martin , chelala , balkwill and fitzgibbon (2016). Reduced expression of histone methyltransferases KMT2C and KMT2D correlates with improved outcome in pancreatic ductal adenocarcinoma. American Association for Cancer Research Cancer Research Carapuça EF, Gemenetzidis E, Feig C, Bapiro TE, Williams MD, Wilson AS, Delvecchio FR, Arumugam P, Grose RP, Lemoine NR, Richards FM and Kocher HM (2016). Anti-stromal treatment together with chemotherapy targets multiple signalling pathways in pancreatic adenocarcinoma. Wiley Journal of Pathology vol. 239, (3) 286-296. Tanner Y and Grose RP (2016). Dysregulated FGF signalling in neoplastic disorders. Elsevier: 12 months Seminars in Cell and Developmental Biology vol. 53, 126-135. 2015
Milagre CS, Gopinathan G, Everitt G, Thompson RG, Kulbe H, Zhong H, Hollingsworth RE, Grose R, Bowtell DDL, Hochhauser D and Balkwill FR (2015). Adaptive Upregulation of EGFR Limits Attenuation of Tumor Growth by Neutralizing IL6 Antibodies, with Implications for Combined Therapy in Ovarian Cancer. American Association for Cancer Research (AACR) Cancer Research vol. 75, (7) 1255-1264. Fearon AE, Chioni A-M and Grose RP (2015). The FGFR Receptor Family. Receptor Tyrosine Kinases: Family and Subfamilies Springer Nature 2014
Carter EP, Fearon AE and Grose RP (2014). Careless talk costs lives: fibroblast growth factor receptor signalling and the consequences of pathway malfunction. Elsevier Trends in Cell Biology vol. 25, (4) 221-233. Coleman SJ, Bruce C, Chioni A-M, Kocher HM and Grose RP (2014). The ins and outs of fibroblast growth factor receptor signalling. Clin Sci (Lond) vol. 127, (4) 217-231. Coleman SJ, Watt J, Arumugam P, Solaini L, Carapuca E, Ghallab M, Grose RP and Kocher HM (2014). Pancreatic cancer organotypics: High throughput, preclinical models for pharmacological agent evaluation. World J Gastroenterol vol. 20, (26) 8471-8481. Yeste-Velasco M, Mao X, Grose R, Kudahetti SC, Lin D, Marzec J, Vasiljević N, Chaplin T, Xue L, Xu M, Foster JM, Karnam SS, James SY, Chioni A-M, Gould D, Lorincz AT, Oliver RTD, Chelala C, Thomas GM, Shipley JM, Mather SJ, Berney DM, Young BD and Lu Y-J (2014). Identification of ZDHHC14 as a novel human tumour suppressor gene. J Pathol vol. 232, (5) 566-577. Coleman SJ, Chioni A-M, Ghallab M, Anderson RK, Lemoine NR, Kocher HM and Grose RP (2014). Nuclear translocation of FGFR1 and FGF2 in pancreatic stellate cells facilitates pancreatic cancer cell invasion. EMBO Mol Med vol. 6, (4) 467-481. Fearon AE and Grose RP (2014). Grb-ing receptor activation by the tail. Nat Struct Mol Biol vol. 21, (2) 113-114. 2013
Fearon AE, Gould CR and Grose RP (2013). FGFR signalling in women's cancers. Int J Biochem Cell Biol vol. 45, (12) 2832-2842. Guasti L, Candy Sze WC, McKay T, Grose R and King PJ (2013). FGF signalling through Fgfr2 isoform IIIb regulates adrenal cortex development. Mol Cell Endocrinol vol. 371, (1-2) 182-188. Galavotti S, Bartesaghi S, Faccenda D, Shaked-Rabi M, Sanzone S, McEvoy A, Dinsdale D, Condorelli F, Brandner S, Campanella M, Grose R, Jones C and Salomoni P (2013). The autophagy-associated factors DRAM1 and p62 regulate cell migration and invasion in glioblastoma stem cells. Oncogene vol. 32, (6) 699-712. Robbez-Masson LJ, Bödör C, Jones JL, Hurst HC, Fitzgibbon J, Hart IR and Grose RP (2013). Functional analysis of a breast cancer-associated FGFR2 single nucleotide polymorphism using zinc finger mediated genome editing. PLoS One vol. 8, (11) 2012
Meyer M, Müller A-K, Yang J, Moik D, Ponzio G, Ornitz DM, Grose R and Werner S (2012). FGF receptors 1 and 2 are key regulators of keratinocyte migration in vitro and in wounded skin. J Cell Sci vol. 125, (Pt 23) 5690-5701. Chioni A-M and Grose R (2012). FGFR1 cleavage and nuclear translocation regulates breast cancer cell behavior. J Cell Biol vol. 197, (6) 801-817. Tsang SM, Brown L, Lin K, Liu L, Piper K, O'Toole EA, Grose R, Hart IR, Garrod DR, Fortune F and Wan H (2012). Non-junctional human desmoglein 3 acts as an upstream regulator of Src in E-cadherin adhesion, a pathway possibly involved in the pathogenesis of pemphigus vulgaris. J Pathol vol. 227, (1) 81-93. Jarosz M, Robbez-Masson L, Chioni A-M, Cross B, Rosewell I and Grose R (2012). Fibroblast growth factor 22 is not essential for skin development and repair but plays a role in tumorigenesis. PLoS One vol. 7, (6) 2010
Yang J, Meyer M, Müller A-K, Böhm F, Grose R, Dauwalder T, Verrey F, Kopf M, Partanen J, Bloch W, Ornitz DM and Werner S (2010). Fibroblast growth factor receptors 1 and 2 in keratinocytes control the epidermal barrier and cutaneous homeostasis. J Cell Biol vol. 188, (6) 935-952. Turner N and Grose R (2010). Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer vol. 10, (2) 116-129. Chioni A-M, Shao D, Grose R and Djamgoz MBA (2010). Protein kinase A and regulation of neonatal Nav1.5 expression in human breast cancer cells: activity-dependent positive feedback and cellular migration. Int J Biochem Cell Biol vol. 42, (2) 346-358. D'Amico G, Jones DT, Nye E, Sapienza K, Ramjuan AR, Reynolds LE, Robinson SD, Kostourou V, Martinez D, Aubyn D, Grose R, Thomas GJ, Spencer-Dene B, Zicha D, Davies D, Tybulewicz V and Hodivala-Dilke KM (2010). Regulation of lymphatic-blood vessel separation by endothelial Rac1 (vol 136, pg 4043, 2009). DEVELOPMENT vol. 137, (2) 359-359. Tsang SM, Liu L, Teh M-T, Wheeler A, Grose R, Hart IR, Garrod DR, Fortune F and Wan H (2010). Desmoglein 3, via an interaction with E-cadherin, is associated with activation of Src. PlosOne PloS ONE vol. 5, (12) 2009
Chioni A-M and Grose R (2009). Negative regulation of fibroblast growth factor 10 (FGF-10) by polyoma enhancer activator 3 (PEA3). Eur J Cell Biol vol. 88, (7) 371-384. 2008
Chioni A-M and Grose R (2008). Organotypic modelling as a means of investigating epithelial-stromal interactions during tumourigenesis. Fibrogenesis Tissue Repair vol. 1, (1) 2007
Grose R, Fantl V, Werner S, Chioni A-M, Jarosz M, Rudling R, Cross B, Hart IR and Dickson C (2007). The role of fibroblast growth factor receptor 2b in skin homeostasis and cancer development. EMBO J vol. 26, (5) 1268-1278. 2005
Grose R and Dickson C (2005). Fibroblast growth factor signaling in tumorigenesis. Cytokine Growth Factor Rev vol. 16, (2) 179-186. Reynolds LE, Conti FJ, Lucas M, Grose R, Robinson S, Stone M, Saunders G, Dickson C, Hynes RO, Lacy-Hulbert A and Hodivala-Dilke K (2005). Accelerated re-epithelialization in beta3-integrin-deficient- mice is associated with enhanced TGF-beta1 signaling. Nat Med vol. 11, (2) 167-174. 2004
Grose R and Werner S (2004). Wound-healing studies in transgenic and knockout mice. Mol Biotechnol vol. 28, (2) 147-166. Zhang HB, Dessimoz J, Beyer TA, Krampert M, Williams LT, Werner S and Grose R (2004). Fibroblast growth factor receptor 1-lllb is dispensable for skin morphogenesis and wound healing. EUR J CELL BIOL vol. 83, (1) 3-11. Grose R (2004). Common ground in the transcriptional profiles of wounds and tumors. Genome Biol vol. 5, (6) 2003
Young P, Boussadia O, Halfter H, Grose R, Berger P, Leone DP, Robenek H, Charnay P, Kemler R and Suter U (2003). E-cadherin controls adherens junctions in the epidermis and the renewal of hair follicles. EMBO J vol. 22, (21) 5723-5733. Petiot A, Conti FJA, Grose R, Revest J-M, Hodivala-Dilke KM and Dickson C (2003). A crucial role for Fgfr2-IIIb signalling in epidermal development and hair follicle patterning. Development vol. 130, (22) 5493-5501. Grose R (2003). Epithelial migration: open your eyes to c-Jun. Curr Biol vol. 13, (17) R678-R680. Beyer TA, Werner S, Dickson C and Grose R (2003). Fibroblast growth factor 22 and its potential role during skin development and repair. EXP CELL RES vol. 287, (2) 228-236. Werner S and Grose R (2003). Regulation of wound healing by growth factors and cytokines. Physiol Rev vol. 83, (3) 835-870. Martin P, D'Souza D, Martin J, Grose R, Cooper L, Maki R and McKercher SR (2003). Wound healing in the PU.1 null mouse--tissue repair is not dependent on inflammatory cells. Curr Biol vol. 13, (13) 1122-1128. Grose R and Werner S (2003). Wound Healing Studies in Transgenic and Knockout Mice. Wound Healing Springer Nature Grose R and Werner S (2003). Wound healing studies in transgenic and knockout mice. A review. Methods Mol Med vol. 78, 191-216. 2002
Wood W, Jacinto A, Grose R, Woolner S, Gale J, Wilson C and Martin P (2002). Wound healing recapitulates morphogenesis in Drosophila embryos. NAT CELL BIOL vol. 4, (11) 907-912. Grose R, Werner S, Kessler D, Tuckermann J, Huggel K, Durka S and Reichardt HM (2002). A role for endogenous glucocorticoids in wound repair. EMBO Rep vol. 3, (6) 575-582. Grose R, Hutter C, Bloch W, Thorey I, Watt FM, Fässler R, Brakebusch C and Werner S (2002). A crucial role of beta 1 integrins for keratinocyte migration in vitro and during cutaneous wound repair. Development vol. 129, (9) 2303-2315. Grose R and Werner S (2002). An aPPARently protective mechanism for keratinocytes in wounded skin. TRENDS MOL MED vol. 8, (4) 149-151. Grose R, Harris BS, Cooper L, Topilko P and Martin P (2002). Immediate early genes krox-24 and krox-20 are rapidly up-regulated after wounding in the embryonic and adult mouse. Dev Dyn vol. 223, (3) 371-378. 2000
Bloch W, Huggel K, Sasaki T, Grose R, Bugnon P, Addicks K, Timpl R and Werner S (2000). The angiogenesis inhibitor endostatin impairs blood vessel maturation during wound healing. Wiley The FASEB Journal vol. 14, (15) 2373-2376. Brakebusch C, Grose R, Quondamatteo F, Ramirez A, Jorcano JL, Pirro A, Svensson M, Herken R, Sasaki T, Timpl R, Werner S and Fässler R (2000). Skin and hair follicle integrity is crucially dependent on β1 integrin expression on keratinocytes. Springer Nature The EMBO Journal vol. 19, (15) 3990-4003. 1999
Grose R and Martin P (1999). Parallels between wound repair and morphogenesis in the embryo. Elsevier Seminars in Cell and Developmental Biology vol. 10, (4) 395-404. Grants
British Council Scholarships for Women in STEM – Academic Year 2024-25Richard Grose
£180,000 British Council (01-12-2023 - 31-03-2026)
Deconvoluting cellular crosstalk in pancreatic cancer invasionRichard Grose
£49,511 Barts and the London Charity (01-09-2021 - 31-12-2022)
TRACER 3D cultures to unravel the role of myoepithelial cells in breast cancer progressionRichard Grose
£13,363 NERC Natural Environment Research Council (01-09-2021 - 31-08-2022)
Exploring the role of adenosine axis in the tumour microenvironment of pancreatic cancerRichard Grose
£107,971 Barts and the London Charity (01-09-2019 - 28-02-2023)
Myoepithelial degradome in the progression of DCIS to invasiveRichard Grose
£477,911 CR-UK Cancer Research UK (01-02-2019 - 31-08-2023)